➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
Harvard Business School
Johnson and Johnson
Merck
Express Scripts

Last Updated: October 31, 2020

DrugPatentWatch Database Preview

Claims for Patent: 4,649,049

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 4,649,049
Title: Rabies vaccine
Abstract:A rabies vaccine composition is disclosed which comprises a sterilized suspension of proteineous suckling mice or rat brain particles of injectable particle size laden with an amount of inactivated rabies virus which is equivalent to a virus titer of at least 10.sup.5.0 to about 10.sup.6 MLD.sub.50 per 0.1 milliliter thereof at a brain tissue concentration of from about 0.3% to about 5.0% by weight, in physiological buffer solution having a pH of between about 7.5 and about 8.0 and comprising an amount dissolved therein, of between 0.02 and 0.08, preferably 0.04, moles per liter, of a buffer composition comprising a mixture of an organic base formula ##STR1## wherein R.sub.1 and R.sub.2 each are CH.sub.2, C.sub.2 H.sub.4 or C.sub.3 H.sub.6, preferably C.sub.2 H.sub.4 combined with between 0.03 and 0.12, preferably 0.06 moles per liter of its corresponding salt, preferable sodium salt. The presence of ethylene maleic anhydride enhances the effectiveness of the composition. The vaccine composition exhibits a high potency and its pH value remains stable over a prolonged period of time.
Inventor(s): Wilson; Jan S. (Fort Dodge, IA)
Assignee: American Home Products Corporation (New York, NY)
Application Number:06/629,307
Patent Claims:1. A rabies vaccine composition comprising a sterilized suspension of at least about 0.3% by weight of proteinaceous suckling mice or rat brain particles of injectable particle size laden with inactivated rabies virus, in an aqueous buffer solution having a slightly basic pH value and an amount, dissolved therein, of a buffer composition sufficient to stabilize the pH at said value, said buffer composition comprising a mixture of an organic base of between 0.02 and 0.08 moles per liter, of a buffer composition comprising an organic base formula ##STR3## wherein R.sub.1 and R.sub.2 are CH.sub.2, C.sub.2 H.sub.4 or C.sub.3 H.sub.6, combined with an acid addition salt thereof, which is compatible with virus replication.

2. A rabies vaccine composition comprising a sterilized suspension of proteinaceous suckling mice or rat brain particles of injectable particle size laden with an amount of inactivated rabies virus which is equivalent to a virus titer of from at least about 10.sup.5 to about 10.sup.6 MLD.sub.50 per 0.1 milliliter thereof, at a brain tissue concentration of from about 0.7 to about 1.2% by weight, in an aqueous buffer solution having a pH between about 7.5 and about 8.0 and comprising an amount dissolved therein of about 0.02 to 0.08 moles per liter, of a buffer composition comprising of an organic base formula ##STR4## wherein R.sub.1 and R.sub.2 are CH.sub.2, C.sub.2 H.sub.4 or C.sub.3 H.sub.6, combined with about 0.03 and 0.12 moles per liter of an acid addition salt thereof.

3. The rabies vaccine composition as defined in claim 2, wherein the buffer composition comprises a mixture of N-2 hydroxyethylpiperazine-N-2 ethanesulfonic acid and its sodium salt.

4. The rabies vaccine composition as defined in claim 3, wherein in the buffer composition the weight ratio of N-2 hydroxyethylpiperazine-N-2 ethanesulfonic acid and its sodium salt is from about 1.0/1.0 to 1.0/4.0.

5. The rabies vaccine composition as defined in claim 4, wherein the weight ratio is about 15.62/9.53.

6. The rabies vaccine composition as defined in claim 2, wherein said aqueous buffer solution is a 0.04 molar solution of said buffer composition.

7. The rabies vaccine composition as defined in claim 2, wherein said brain particles are laden with an amount of said inactivated rabies virus which is equivalent to a virus titer of from at least about 10.sup.5 to about 10.sup.6 MLD.sub.50 per 0.1 milliliter of said suspension.

8. The rabies vaccine composition as defined in claim 2, wherein the particle size of the brain particles is between about 1 and about 10 microns.

9. The rabies vaccine composition as defined in claim 2, wherein the organic base is N-2-hydroxyethylpiperazine-N-3 propane sulfonic acid.

10. The rabies vaccine composition as defined in claim 2 which comprises between about 0.7 to 1.2 percent by weight of brain particles.

11. The rabies vaccine composition as defined in claim 2 in which the amount of brain particles is about 1.2 percent by weight.

12. The rabies vaccine composition as defined in claim 2 further containing an adjuvant.

13. The rabies vaccine composition as defined in claim 12 where said adjuvant is ethylene maleic anhydride.

14. The rabies vaccine composition as defined in claim 13 where said ethylene maleic anhydride is present in the amount of 1.2 to 2.2 mgs per dose.

15. A veterinary rabies vaccine composition comprising an effective amount of a rabies virus antigen, a pharmaceutically acceptable carrier and an effective amount of ethylene maleic anhydride.

Details for Patent 4,649,049

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Glaxosmithkline Biologicals Sa RABAVERT rabies vaccine KIT 103334 1 2016-12-19   Start Trial American Home Products Corporation (New York, NY) 2040-01-28 search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
AstraZeneca
Dow
McKinsey
Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.